Celltrion Files Petitions for IPR of Three Rituximab Patents

PTAB + IPR

Celltrion has filed three petitions for IPR of Biogen’s patents related to rituximab:  IPR2017-01093, challenging U.S. Patent 8,329,172; IPR2017-01094 challenging U.S. Patent 8,557,244; and IPR2017-01095 challenging U.S. Patent 9,296,821.  Rituximab is marketed under the trade-name Rituxan® by Genentech and Biogen, and is indicated for the treatment of some cancers and autoimmune diseases.

These petitions and other important filings related to IPRs on biologic patents are posted on our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.